Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma, Angle-Closure | 1 | 2025 | 23 | 0.890 |
Why?
|
| Bupropion | 1 | 2025 | 47 | 0.880 |
Why?
|
| Hamartoma | 1 | 2021 | 29 | 0.690 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2021 | 40 | 0.680 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2021 | 46 | 0.680 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2020 | 8 | 0.650 |
Why?
|
| Transduction, Genetic | 1 | 2020 | 133 | 0.610 |
Why?
|
| Adenoviridae | 1 | 2020 | 199 | 0.600 |
Why?
|
| Genetic Vectors | 1 | 2020 | 337 | 0.570 |
Why?
|
| Diabetic Retinopathy | 1 | 2021 | 208 | 0.560 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2020 | 266 | 0.550 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2020 | 452 | 0.520 |
Why?
|
| Endothelial Cells | 1 | 2020 | 870 | 0.410 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 1098 | 0.360 |
Why?
|
| Drug Repositioning | 1 | 2026 | 41 | 0.230 |
Why?
|
| Microscopy, Acoustic | 1 | 2025 | 10 | 0.230 |
Why?
|
| Gonioscopy | 1 | 2025 | 12 | 0.230 |
Why?
|
| Atropine | 1 | 2025 | 37 | 0.230 |
Why?
|
| Macular Degeneration | 1 | 2026 | 191 | 0.200 |
Why?
|
| Tomography, Optical Coherence | 1 | 2025 | 271 | 0.190 |
Why?
|
| Retinopathy of Prematurity | 1 | 2025 | 179 | 0.190 |
Why?
|
| Intraocular Pressure | 1 | 2025 | 328 | 0.190 |
Why?
|
| Vitreoretinopathy, Proliferative | 1 | 2022 | 15 | 0.190 |
Why?
|
| Acute Disease | 1 | 2025 | 1031 | 0.180 |
Why?
|
| Endophthalmitis | 1 | 2022 | 45 | 0.180 |
Why?
|
| Eye Infections, Bacterial | 1 | 2022 | 44 | 0.180 |
Why?
|
| Retinal Detachment | 1 | 2022 | 73 | 0.170 |
Why?
|
| Retina | 2 | 2021 | 324 | 0.170 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2021 | 80 | 0.170 |
Why?
|
| Urban Health | 1 | 2021 | 96 | 0.160 |
Why?
|
| Hexadimethrine Bromide | 1 | 2020 | 1 | 0.160 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2020 | 25 | 0.160 |
Why?
|
| Photography | 1 | 2021 | 115 | 0.160 |
Why?
|
| ADAM17 Protein | 1 | 2020 | 42 | 0.160 |
Why?
|
| Cataract | 1 | 2022 | 238 | 0.150 |
Why?
|
| General Surgery | 1 | 2021 | 207 | 0.140 |
Why?
|
| Green Fluorescent Proteins | 1 | 2020 | 405 | 0.140 |
Why?
|
| Liposomes | 1 | 2020 | 250 | 0.140 |
Why?
|
| Medicare | 1 | 2022 | 887 | 0.120 |
Why?
|
| Gelsolin | 1 | 2016 | 10 | 0.120 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 367 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 1990 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 2540 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 1099 | 0.100 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 205 | 0.100 |
Why?
|
| Trophoblasts | 1 | 2016 | 216 | 0.100 |
Why?
|
| Extracellular Vesicles | 1 | 2016 | 171 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 848 | 0.100 |
Why?
|
| Recombinant Proteins | 1 | 2016 | 1371 | 0.100 |
Why?
|
| Pandemics | 1 | 2021 | 1695 | 0.090 |
Why?
|
| Humans | 11 | 2026 | 144957 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2020 | 4155 | 0.090 |
Why?
|
| Mass Screening | 1 | 2021 | 1348 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 1322 | 0.090 |
Why?
|
| Rats | 1 | 2020 | 5614 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2021 | 1257 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 5997 | 0.070 |
Why?
|
| Aged | 3 | 2026 | 25947 | 0.070 |
Why?
|
| Male | 4 | 2025 | 72406 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2025 | 17101 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 5417 | 0.050 |
Why?
|
| Middle Aged | 1 | 2025 | 35928 | 0.050 |
Why?
|
| Ranibizumab | 1 | 2022 | 21 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2022 | 80 | 0.050 |
Why?
|
| Metformin | 1 | 2026 | 319 | 0.050 |
Why?
|
| Intravitreal Injections | 1 | 2022 | 71 | 0.050 |
Why?
|
| Silicone Oils | 1 | 2022 | 34 | 0.050 |
Why?
|
| Animals | 2 | 2026 | 38109 | 0.050 |
Why?
|
| Adolescent | 1 | 2021 | 22453 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2022 | 167 | 0.040 |
Why?
|
| Female | 3 | 2025 | 78376 | 0.040 |
Why?
|
| Gestational Age | 1 | 2025 | 975 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2022 | 237 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 557 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2026 | 1339 | 0.040 |
Why?
|
| Universities | 1 | 2021 | 452 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 357 | 0.030 |
Why?
|
| Rural Population | 1 | 2021 | 650 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2026 | 1389 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2016 | 83 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2016 | 74 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2016 | 115 | 0.030 |
Why?
|
| United States | 2 | 2022 | 15988 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2025 | 6434 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 5872 | 0.020 |
Why?
|
| Infant | 1 | 2025 | 10039 | 0.020 |
Why?
|
| Risk Factors | 1 | 2025 | 10792 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 3608 | 0.020 |
Why?
|
| Pregnancy | 1 | 2016 | 7191 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 14126 | 0.010 |
Why?
|
| Adult | 1 | 2016 | 40506 | 0.010 |
Why?
|